A5088037866- Pharmaceutical Economics and Policy
- Health Systems, Economic Evaluations, Quality of Life
- Economic and Financial Impacts of Cancer
- Chronic Myeloid Leukemia Treatments
- Diabetes Treatment and Management
- Pharmacovigilance and Adverse Drug Reactions
- Pharmaceutical studies and practices
- Urticaria and Related Conditions
- Drug-Induced Adverse Reactions
- Eosinophilic Disorders and Syndromes
- Pharmaceutical industry and healthcare
Maccabi Health Care Services
2022-2024
Despite a favorable effect of imatinib on glucose metabolism in animal models, human reports are inconsistent. We retrospectively studied the long-term fasting plasma (FPG), glycated hemoglobin (HbA1C), LDL-cholesterol (LDL), and triglycerides (TGs) large HMO cohort patients initiating therapy. In with diabetes (n = 118), significant reductions HbA1c (0.53%, IQR 0.09, 1.19; p < .001) FPG (10.2 mg/dL, -3.5, 32.2; .001), independent demographics glucose-lowering drugs utilization, were...
In Israel, coverage of health needs is delivered by four maintenance organizations (HMOs), which are budgeted the government according to recommendations National Drug Formulary (NDF) Committee. For medications not listed in NDF, individuals may request cover costs HMO Exemptions Committee (DEC). The objectives current study, a first its kind, document DEC decision process, identify components and determine decisions' clinical outcome.
e18599 Background: The Israeli National Insurance Law determines a uniform benefits package ('the Health Basket') for all residents. A public committee advises each year on which new medications should be added to the Basket, subject fixed annum budget allocated by government this purpose. clinical benefit of proposed health technologies is committee's prime consideration; however, also considers professional medical societies' prioritizations, expected impact, and other social ethical...
PURPOSE In Israel, a public committee advises which new medications should be reimbursed subject to an annual budget allocation. The considers clinical trial outcomes, professional societies' preferences, projected impacts, and other social ethical aspects. Israeli oncologists' society places strong emphasis on prioritizing adjuvant therapies because of their potential advance cure. 2023, several novel were suggested for national funding. Our objective was ascertain whether decision makers...
<title>Abstract</title> Background In Israel, coverage of health needs is delivered by four maintenance organizations (HMOs), which are budgeted the government according to recommendations National Drug Formulary (NDF) Committee. For medications not listed in NDF, individuals may request cover costs HMO Exemptions Committee (DEC). The objectives current study, a first its kind, document DEC decision process, identify components as formalized USA (Eddy criteria) and determine decisions'...